drugset / Trial / NCT07807722
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
NaSingle-groupOpen-labelTreatment
Summary
Exploring the efficacy and safety of firmonertinib combined with anlotinib and platinum-based doublet chemotherapy as neoadjuvant therapy in patients with EGFR-mutant resectable NSCLC
Timeline
- Start
- 2026-09-21
- Primary completion
- 2028-03
- Completion
- 2030-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Catequentinib | Small molecule | 8 mg | — |
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Firmonertinib | Small molecule | 80 mg | — |
| Subject | Pemetrexed | Small molecule | — | — |